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Sarcopenia and change in body composition
following maximal androgen suppression
with abiraterone in men with castration-
resistant prostate cancer
C Pezaro1,2, D Mukherji1,2, N Tunariu1, A M Cassidy1, A Omlin1, D Bianchini1, G Seed1, A H M Reid1,
D Olmos1, J S de Bono1,3 and G Attard*,1,3
1Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The
Institute of Cancer Research, Downs Road, Sutton, Surrey, UK
Background: Standard medical castration reduces muscle mass. We sought to characterize body composition changes in men
undergoing maximal androgen suppression with and without exogenous gluocorticoids.
Methods: Cross-sectional areas of total fat, visceral fat and muscle were measured on serial CT scans in a post-hoc analysis of
patients treated in Phase I/II trials with abiraterone followed by abiraterone and dexamethasone 0.5mg daily. Linear mixed
regression models were used to account for variations in time-on-treatment and baseline body mass index (BMI).
Results: Fifty-five patients received a median of 7.5 months abiraterone followed by 5.4 months abiraterone and dexamethasone.
Muscle loss was observed on single-agent abiraterone (maximal in patients with baseline BMI 430,  4.3%), but no further loss
was observed after addition of dexamethasone. Loss of visceral fat was also observed on single-agent abiraterone, (baseline BMI
430 patients  19.6%). In contrast, addition of dexamethasone led to an increase in central visceral and total fat and BMI in all the
patients.
Interpretation: Maximal androgen suppression was associated with loss of muscle and visceral fat. Addition of low dose
dexamethasone resulted in significant increases in visceral and total fat. These changes could have important quality-of-life
implications for men treated with abiraterone.
Androgens, together with growth hormone mimetics and follista-
tin, activate anabolic pathways in a process that results in the
accrual of muscle mass (Basaria and Bhasin, 2012). Androgens are
therefore an important determinant of body composition in men.
In fact, serum testosterone concentrations correlate positively with
muscle and negatively with fat mass (Vermeulen et al, 1999). A
change in body composition, with loss of muscle mass and
increased subcutaneous and visceral abdominal fat, is widely
recognised as an adverse effect of castration for men with prostate
cancer (Lee et al, 2005; Hamilton et al, 2011; Smith et al, 2012).
Skeletal muscle depletion is associated with reduced functional
ability and increased mortality (Fearon et al, 2011) and may also
contribute to the increased cardio-metabolic risk associated with
androgen-deprivation therapy (Basaria and Bhasin, 2012). Testos-
terone levels decline from 450 ng dl 1 to a median of 7 ng dl 1
following castration for prostate cancer (Attard et al, 2008; Ryan
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et al, 2010). Treatment of castration-resistant prostate cancer
(CRPC) with abiraterone, a selective inhibitor of CYP17A1, results
in a further decline in serum testosterone too0.9 ng dl 1 (Attard
et al, 2012). A decline in cortisol associated with a compensatory
rise in adrenocorticotrophic hormone and a consequent syndrome
of secondary mineralocorticoid excess in most patients treated with
abiraterone alone has led to its development in combination with
exogenous glucocorticoids, most commonly prednisone 5mg bid.
Abiraterone improves the survival of men with docetaxel-
treated and chemotherapy-naive CRPC (de Bono et al, 2011; Ryan
et al, 2013). As abiraterone is better tolerated than chemotherapy,
it is anticipated that it will be increasingly widely used before
chemotherapy. A change in body composition with abiraterone
could have important implications for the quality of life of men
with advanced prostate cancer, especially men who are asympto-
matic or minimally symptomatic. If recognized, body composition
changes can be addressed through exercise interventions (Segal
et al, 2003; Galvao et al, 2010). We hypothesized that both
abiraterone and exogenous glucocorticoids could affect body
composition, and we therefore separately evaluated the effects of
abiraterone alone (resulting in ‘super-castrate’ levels of serum
androgens) and after addition of exogenous glucocorticoids to
abiraterone in men with progressive CRPC.
MATERIALS AND METHODS
Patients. All patients treated with single-agent abiraterone in
clinical trials at the Royal Marsden NHS Foundation Trust, UK
(COU-AA-001 (Attard et al, 2009), COU-AA-003 (Reid et al,
2010) and COU-Bioequivalence (Carden et al, 2008)) were
considered for this post-hoc analysis. Entry to these trials required
histological evidence of prostate adenocarcinoma with progressing
disease by Prostate Working Group criteria (Bubley et al, 1999),
adequate bone marrow, renal and hepatic function and good
performance status; without brain metastases, spinal cord com-
pression, uncontrolled hypertension or serious concurrent medical
illness. All patients maintained a castrate state throughout study
participation by means of ongoing LHRH analogue therapy or
surgical castration. These trials allowed addition of dexamethasone
0.5mg daily at PSA progression on abiraterone alone or for
management of abiraterone-related toxicity. Dexamethasone was
utilized in preference to prednisone due to higher activity reported
in CRPC (Venkitaraman et al, 2008), less mineralocorticoid
activity (Lan et al, 1982) and to evaluate re-induction of sensitivity
to abiraterone in patients who had been previously treated with the
same dose and regimen of glucocorticoid (Attard et al, 2009).
Patients were not provided specific instructions about nutrition or
exercise. Study protocols were approved by the Royal Marsden
institutional research board (IRB), and all patients provided
informed consent for imaging and data collection.
Study design. The primary outcome of this analysis was change of
muscle, subcutaneous fat, visceral fat and total fat area and of body
mass index (BMI) after a minimum of 6 weeks treatment with
single-agent abiraterone and a minimum of 6 weeks treatment with
abiraterone combined with dexamethasone. Previous studies have
shown linear relationships between lumbar skeletal muscle and fat
cross-sectional areas measured using multiple-slice computed
tomography (CT) and whole-body muscle and fat mass measured
using dedicated dual-energy X-ray absorptiometry (DEXA) scans
(Shen et al, 2004; Mourtzakis et al, 2008). We thus were able to use
CT scans performed for clinical or restaging purposes for analyses
of changes in body composition. For this analysis, patients
were required to have three available CT scans: a pretreatment
CT for baseline assessment, a CT following a minimum of
6 weeks treatment on abiraterone alone (before initiation of
dexamethasone; treatment period 1, see Supplementary Table S1)
and a CT after a similar duration of treatment with combination
abiraterone and dexamethasone (treatment period 2). Cross-
sectional areas of muscle were averaged from two consecutive
CT slices at the L3 level as has been described previously (Prado
et al, 2008; Antoun et al, 2010) using OsiriX version 4.0 (Pixmeo,
Geneva, Switzerland) and Slice-O-Matic version 4.3 (TomoVision,
Magog, QC, Canada) software. Total fat and visceral fat were
measured at the L4 level using the same technique. Subcutaneous
fat was manually calculated from the difference between total and
visceral fat. Measurements were undertaken by three trained
assessors (CP, DM, GS) and were independently reviewed by a
radiologist (NT). Anthropomorphic measurements of height at
baseline and weight at each assessment point were used to calculate
BMI (expressed as kgm 2).
Statistical analysis. Changes in body composition were assessed
by baseline BMI status (o25, 25–30, 430) as the relative change
in body composition on treatment was expected to vary between
these baseline groups. Unlike the fixed treatment intervals used in
adjuvant hormone schedules, CRPC patients receive abiraterone
for highly variable periods of time. The inter-scan intervals (from
start to completion of treatment, see Supplementary Table S1)
therefore differ between patients, and observed changes in body
composition could be similarly expected to depend on the length of
treatment patients received. Thus a model-based approach was used,
with selection of linear mixed regression models to account for the
natural correlation among repeated measures (Verbeke and
Molenberghs, 2000). The individual patient data were incorporated
in this model to account for variability in scan intervals, and all
results represent estimated change after 6 months on the reported
treatment combination. Predictor variables were abiraterone and
dexamethasone treatment, time on abiraterone, time on dexametha-
sone and interactions between these variables and the baseline BMI
group. These interactions allowed for potentially different slopes and
effects in the different BMI groups. Models were built separately for
muscle, total fat, visceral fat and subcutaneous fat areas and BMI, all
of which were log transformed for analysis. The mean (and 95%
confidence interval (CI)) effect estimates were derived from linear
combinations of coefficients from these models at fixed time points,
which were selected to represent the average length of time spent
on the different treatment combinations. Two-sided P values
are reported, and a P value o0.05 was considered statistically
significant. Interaction P values were provided to demonstrate
whether the changes observed were different between the baseline
BMI groups. Due to the predefined study endpoints, no adjustment
for multiplicity was considered necessary (Rothman, 1990). Analyses
were performed using Stata version 12 (StataCorp LP, College
Station, TX, USA) by an experienced biostatistician (AMC). Pearson
correlation analyses were performed using GraphPad Prism version
5.0a (Graphpad Software, San Diego, CA, USA).
RESULTS
Patient characteristics. Of the 96 patients treated with abiraterone
in early clinical trials that evaluated abiraterone alone followed by
abiraterone and dexamethasone at the Royal Marsden Hospital,
only 55 patients were eligible for body composition analyses
(Figure 1, patient characteristics described in Table 1 and
Supplementary Table S2). All subsequent studies have utilised
combinations of abiraterone and exogenous glucocorticoids, and
this therefore represents a unique population for evaluating the
effect of ‘super-castration’ without the confounding factors
introduced by concomitant exogenous glucocorticoids. The
majority of patients were of European descent (53 Caucasian,
1 Black African, 1 Black Caribbean) and 46 patients were
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docetaxel-naive. Before starting treatment, 10 (18%) patients had a
BMI o25, 26 (47%) had a BMI 25–30 and 19 (35%) had a BMI
430. Patients received a median of 7.5 months abiraterone alone
and 5.4 months abiraterone and dexamethasone. At the CT scan
evaluating change on abiraterone alone, 46 patients had a
confirmed rise in PSA as defined by PSAWG I (Bubley et al,
1999), 3 (of 46) had soft-tissue progression on CT scan and three
patients had progression on bone scan. Of the nine patients
without PSA progression, five had toxicity and four required
addition of dexamethasone following a protocol amendment
(Supplementary Table S1). At the scan evaluating change on
abiraterone and dexamethasone, 33 patients had a confirmed rise
in PSA (7 (of 33) had soft-tissue progression on CT scan and 9 had
progression on bone scan), and 22 patients had an ongoing
response or stable disease and continued on study treatment.
Assessment of muscle mass and body fat using CT scans. Two
software packages for evaluating body composition (OsiriX and
Slice-O-Matic; Figure 2, Supplementary Figure S1) were first used
to evaluate pretreatment scans by operators blinded to each other’s
results. There was strong correlation between area measurements
with the two software techniques, with r-values of 0.96 for total fat,
0.94 for visceral fat and 0.80 for muscle. Both software platforms
were equally user friendly, and OsiriX was selected due to
individual operator choice. Baseline BMI was compared with
measurements of cross-sectional areas of fat and muscle. Total fat
(r¼ 0.85) and subcutaneous fat (r¼ 0.83) strongly correlated with
BMI and visceral fat and muscle were less strongly correlated
(r¼ 0.59 and 0.65, respectively) (Supplementary Figure S2).
Changes in muscle and fat on treatment with abiraterone
followed by abiraterone and dexamethasone. Muscle loss was
observed in patients treated with single-agent abiraterone, with loss
greatest in patients with a baseline BMI430 (median change: BMI
o25:  2.9% (95% CI:  6.5, þ 0.8); BMI 25–30,  2.8% (95%
CI:  5.1,  0.5); BMI 430,  4.3% (95% CI:  7.1,  1.5);
Table 2, Figure 3A). There was no further significant change in
muscle mass after the addition of dexamethasone. Surprisingly, loss
of visceral fat was also observed on single-agent abiraterone.
Similarly, this effect was most evident in patients with a baseline
BMI 430 who had a 19.6% (95% CI:  26.9,  11.6%) loss of
visceral fat area (median change: BMI o25:  10.6% (95% CI:
 20.9, 1%); BMI: 25–30:  9.9% (95% CI:  16.6,  2.7%);
Table 2, Figures 3B and C). Loss of subcutaneous fat was less
marked (Table 2, Supplementary Figure S3). In keeping with loss of
fat and muscle with single-agent abiraterone, there was also a
decrease in BMI, again most significant in patients with a baseline
BMI 430 ( 8.1% (95% CI:  10.8,  5.4); Table 2, Figure 3D).
In contrast, the addition of dexamethasone led to a striking
increase in central fat in all the patients regardless of baseline BMI
and most notably visceral (BMIo25: þ 23.6% (95% CI: þ 9.3,
þ 39.8%), BMI 25–30: þ 17.8% (95% CI: þ 9.2, þ 27.1%),
BMI430: þ 27.9% (95% CI: þ 16.9, þ 39.9%)), with a recovery
in fat to pre-abiraterone levels (Table 2, Figures 3B and C). The
change in subcutaneous fat was again less marked (Table 2,
Supplementary Figure S3). Overall, there was a significant increase
in total fat (þ 10.9% (95% CI: þ 0.8, þ 22%)) by completion of
both treatment periods in patients with a baseline BMI o25
(Table 2). After the addition of dexamethasone, all groups
experienced a marked increase in BMI (o25: 6.0% (2.0, 10.2);
25–30: 5.8% (3.3, 8.3); 430: 3.8% (1.0, 6.8)). However, over both
treatment periods there was a median increase in BMI of þ 3.8%
for patients with a baseline BMI o25 (95% CI:  0.2, 8.0) and
1 patient developed ascites that
obscured fat measurements
 
96 patients treated in early
clinical studies of abiraterone
19 patients received exogenous
glucocorticoids with abiraterone
from the start
16 patients never received
exogenous glucocorticoids with
abiraterone
In 3 patients, exogenous
glucocorticoids were added to
abiraterone within 4 weeks
No baseline scan was available
for 2 patients
55 patients eligible for body
composition analyses
Figure 1. Selection of patients for body composition analyses.
Table 1. Demographics of patients included in body composition analysis
(n¼ 55)
Population, n¼55
Median
(range) N (%)
Ethnicity
Caucasian 53 (96)
Black African 1 (2)
Black Caribbean 1 (2)
Gleason at diagnosis 8 (4–10)
(NA in 3 patients)
Time from castration to abiraterone, years 3.7 (0.4–13.7)
Baseline PSA 79 (8.8–10 335)
Baseline BMI
o25 10 (18)
25–30 26 (47)
430 19 (35)
Previous glucocorticoid treatment for
prostate cancer
28 (51)
Duration of steroids in pre-chemotherapy
patients, months (n¼17)
11.2 (1.0–38.0)
Steroid-free interval in pre-chemotherapy
patients, months (n¼17)
5.2 (1.2–12.7)
Previous docetaxel treatment 11 (20)
Age at starting abiraterone, years 68 (49–86)
Metastases at baseline
Bone 49 (89)
L/N 30 (55)
Visceral 5 (9)
ECOG performance status
0 37 (67)
1 18 (33)
Overall survival, months 43.7 (range
8.5–75.7a)
Abbreviations: BMI¼body mass index; ECOG¼Eastern Cooperative Oncology Group;
L/N¼ lymph node; NA¼not assessable; PSA¼prostate-specific antigen.
aSurvival data censored as of 4 December 2012.
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26/02/2007 –  Baseline
TF area = 281.2 cm2, VF = 105.4 cm2
14/08/2007 – After A 
TF = 229.1 cm2, VF = 65.2 cm2
24/04/2008 – After A+D
TF = 312.4 cm2, VF = 106.7 cm2
Visceral and subcutaneous fat (TF)
 
Visceral fat (VF)  
14/11/2006  – Baseline
Muscle (M) area = 180.3 cm2
30/07/2007  – After A
M = 162.5 cm2
05/02/2008 – After A+D
M = 166.3 cm2
Figure 2. Analysis of body composition using OsiriX software: (A) total (visceral and subcutaneous) and visceral fat analysis at baseline, (B) after
abiraterone and (A) (C) after abiraterone plus dexamethasone; (AþD) muscle analysis, including psoas, paravertebral and abdominal muscles at
(D) baseline, (E) after abiraterone and (F) after abiraterone plus dexamethasone.
Table 2. Changes in fat and muscle following treatment with abiraterone (abi) and after addition of dexamethasone (dexa) to abiraterone
Change on abi from
baseline
Change on abiþdexa from abi alone Change on abiþdexa from baseline
Relative change at
6 months (95% CI) P-value Int. p
Relative change at
12 months (95% CI) P-value Int. p
Relative change at
12 months (95% CI) P-value Int. p
Muscle
BMIo25 0.971 (0.935, 1.008) 0.1278 0.6840 1.016 (0.978, 1.055) 0.4132 0.5047 0.987 (0.949, 1.026) 0.4969 0.5875
BMI
25–30
0.972 (0.949, 0.995) 0.0191 1.005 (0.982, 1.029) 0.6584 0.977 (0.953, 1.001) 0.0653
BMI430 0.957 (0.929, 0.985) 0.0029 0.990 (0.963, 1.017) 0.4578 0.947 (0.917, 0.977) 0.0007
Total fat
BMIo25 0.935 (0.852, 1.026) 0.1549 0.0573 1.186 (1.081, 1.302) 0.0003 0.2447 1.109 (1.008, 1.220) 0.0341 0.1068
BMI
25–30
0.941 (0.888, 0.998) 0.0426 1.125 (1.062, 1.191) 0.0001 1.059 (0.997, 1.125) 0.0647
BMI430 0.845 (0.786, 0.908) o0.0001 1.211 (1.131, 1.296) o0.0001 1.023 (0.946, 1.106) 0.5725
Visceral fat
BMIo25 0.894 (0.791, 1.010) 0.0725 0.1640 1.236 (1.093, 1.398) 0.0007 0.3832 1.105 (0.973, 1.253) 0.1230 0.3160
BMI
25–30
0.901 (0.834, 0.973) 0.0082 1.178 (1.092, 1.271) o0.0001 1.062 (0.980, 1.150) 0.1431
BMI430 0.804 (0.731, 0.884) o0.0001 1.279 (1.169, 1.399) o0.0001 1.028 (0.928, 1.140) 0.5931
Subcutaneous fat
BMIo25 0.980 (0.864, 1.111) 0.7510 0.2540 1.130 (0.996, 1.282) 0.0581 0.2180 1.107 (0.972, 1.261) 0.1242 0.1562
BMI
25–30
0.975 (0.901, 1.056) 0.5379 1.049 (0.970, 1.134) 0.2326 1.023 (0.942, 1.110) 0.5884
BMI430 0.884 (0.802, 0.974) 0.0131 1.164 (1.061, 1.277) 0.0013 1.029 (0.925, 1.143) 0.6005
BMI
o25 0.979 (0.943, 1.017) 0.2789 0.0043 1.060 (1.020, 1.102) 0.0027 0.5419 1.038 (0.998, 1.080) 0.0619 0.0535
25–30 0.975 (0.952, 0.998) 0.0362 1.058 (1.033, 1.083) o0.0001 1.031 (1.006, 1.057) 0.0154
430 0.919 (0.892, 0.946) o0.0001 1.038 (1.010, 1.068) 0.0084 0.954 (0.924, 0.985) 0.0040
Abbreviations: BMI¼body mass index; CI¼ confidence interval; int. p¼ interaction P value. Changes that are statistically significant shown in bold.
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3.1% in patients with a baseline BMI 25–30 (95% CI: 0.6, 5.7;
Table 2, Figure 3E). In contrast, there was a 4.6% decrease (95% CI:
 7.6,  1.5) in BMI in patients with a baseline BMI 430.
Loss of fat and muscle shows stabilization on castration before
abiraterone treatment. In view of the finding of muscle and fat
loss with abiraterone, we sought to exclude whether this was
ongoing secondary to castration or induced by initiation of
abiraterone. We identified a subset of seven men with CT scans
performed a minimum of 6 months before commencing
abiraterone and who had muscle loss (range: 2.1–17.1% reduction
in area) on single-agent abiraterone. Pretreatment CT scans were
performed a median of 9.7 months earlier (range: 6.5–15.1
months). No patient had muscle loss in this interval (Figure 4),
and there was no consistent effect on visceral or subcutaneous fat
measurements. Moreover, in the entire cohort there was no
correlation between loss of muscle or fat on abiraterone and time
from commencing castration (Supplementary Figure S4).
DISCUSSION
This is the first study to report muscle loss in castrate men caused
by increasing suppression of serum androgens to a ‘super-castrate’
range by abiraterone. This is notable because a significant
proportion of patients remain on abiraterone for many months
and the prevalence and risks of sarcopenia are likely to be
underestimated, despite the potential impact on patients’ quality of
life. Side-effects associated with androgen suppression, including
hot flushes and testicular atrophy, have been reported previously
(Attard et al, 2008; Ryan et al, 2010), but changes in body
composition have, to date, not been studied. Patients with a
pretreatment BMI 430 experienced the most significant loss of
muscle mass. The finding that single-agent abiraterone resulted in
loss of visceral fat in addition to muscle, with a corresponding
decrease in BMI, was unexpected. Small cohort studies utilizing CT
scans have previously reported conflicting effects on visceral fat
with androgen deprivation. A study in 32 men commencing first-
line androgen deprivation suggested no change after 48 weeks on
treatment (Smith et al, 2002), whereas a 22% increase in visceral
abdominal fat was reported in 26 men over the first 12 months of
androgen deprivation (Hamilton et al, 2011). Most studies of
sarcopenia in prostate cancer utilize DEXA scans and therefore
cannot identify changes in visceral fat.
No additional loss of muscle was observed on addition of
dexamethasone to abiraterone. Although this is likely to be a result
of a plateau in muscle loss as has also been observed in men treated
with initial androgen-deprivation therapy (Lee et al, 2005; Smith
et al, 2012), we cannot exclude the possibility that glucocorticoids
initiated with abiraterone would protect against muscle loss. This
could be a consideration for trials utilizing lower dose of exogenous
glucocortiocoids. Sarcopenia could occur secondary to disease
progression, but the absence of significant changes in progressing
patients before initiation of abiraterone (Figure 4), the plateau in
muscle loss maintained after addition of dexamethasone and the
fact that the majority of patients had a rising PSA in the absence of
radiological progression at evaluation for changes on single-agent
abiraterone (Supplementary Table S1) suggest that disease
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Figure 4. Changes in muscle before and after starting abiraterone
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progression cannot explain our findings. Also, there was no
significant gastro-intestinal toxicity with abiraterone that could
explain the loss of muscle and fat observed. Conversely and as
anticipated, there was gain of central fat, most notably visceral, and
BMI on addition of exogenous glucocorticoid (0.5mg dexametha-
sone, equivalent to 5–7.5mg prednisone). In this study, we only
observed a significant gain in fat after completion of both study
periods compared with pre-abiraterone in patients with a BMI
o25. In current routine clinical practice, glucocorticoids are
initiated with abiraterone, and this could change the extent of fat
gain.
These data were obtained in an unplanned post-hoc analysis and
must be regarded as exploratory and hypothesis-generating. The
sample size limited the statistical power for subgroup analyses. The
variability in treatment duration and imaging was accounted for in
the statistical model. However, an important potential confounder
was the previous exposure to glucocorticoid treatment in half of
the subjects. The impact of such treatment would only be explored
through further analysis of larger patient groups. Abiraterone has
now been extensively evaluated in Phase I, II and III clinical trials,
and there are no reports of an association with an increase in
cardio-metabolic events. However, overall these data introduce
important considerations on the long-term implications of
profound androgen suppression. Importantly, they should instigate
further in-depth evaluation of changes in body composition in a
larger cohort of patients using restaging CT scans obtained in the
post- and pre-chemotherapy abiraterone Phase III studies (COU-
301, COU-302), ongoing clinical studies of other C17,20-lyase
inhibitors and prospective Phase IV studies. The incidence of
sarcopenia secondary to other novel hormonal manipulations,
including for example enzalutamide recently shown to improve
overall survival of CRPC patients (Scher et al, 2012), should also be
evaluated.
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